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Background: Persister cells constitute a subpopulation of dormant cells within a microbial population which are
genetically identical but phenotypically different to regular cells. Notably, persister cells show an elevated tolerance
to antimicrobial agents. Thus, they are considered to represent a microbial ‘bet-hedging’ strategy and are of
particular importance in pathogenic bacteria.
Results: We studied the ability of the zoonotic pathogen Streptococcus (S.) suis to form multi-drug tolerant variants
and identified persister cells dependent on the initial bacterial growth phase. We observed lower numbers of
persisters in exponential phase cultures than in stationary growth phase populations. S. suis persister cells showed a
high tolerance to a variety of antibiotics, and the phenotype was not inherited as tested with four passages of
S. suis populations. Furthermore, we provide evidence that the persister phenotype is related to expression of genes
involved in general metabolic pathways since we found higher numbers of persister cells in a mutant strain defective
in the catabolic arginine deiminase system as compared to its parental wild type strain. Finally, we observed persister
cell formation also in other S. suis strains and pathogenic streptococcal species.
Conclusions: Taken together, this is the first study that reports multi-drug tolerant persister cells in the zoonotic
pathogen S. suis.
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Formation of persister cells by bacteria is a phenomenon
that, amongst others, contributes to tolerance of a bacterial
subpopulation to antimicrobial agents. Notably, this anti-
biotic tolerance of persister cells is distinct from genetically
inherited resistance. The persister cell subpopulation has
been firstly described and named nearly 70 years ago [1]
and research on persister cells has identified a number of
typical characteristics as debated recently [2]. Bacterial
persister cells seem to represent a stage of dormancy that
protects them from killing by antimicrobial substances,
even in the presence of concentrations which vastly exceed
the minimal inhibitory concentration (MIC). Persister cells
are genetically identical to antibiotic sensitive bacteria
within a population, but have a distinct phenotype in that
they are tolerant to certain antibiotics [3]. Since most anti-
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article, unless otherwise stated.in replication, the dormancy stage in persister cells is
thought to be the underlying mechanism of antibiotic tol-
erance [4]. Nevertheless, persister celIs can switch from
the dormant into a replicating stage. This ‘bet-hedging’
strategy is thought to be a survival strategy of microbial
populations [5].
Two different types of persister cells have been postu-
lated. Type I persister cells are formed in response to en-
vironmental stimuli, for instance during the initiation of
the stationary growth phase, whereas type II persister cells
arise stochastically within a dividing population [6,7].
A recent report proposed a ‘persistence-if-stuff-happens’
hypothesis, i.e. persister cell formation is an inevitable
process due to cellular errors that produce transient states
of reduced replication and/or metabolic activity in a single
bacterium [8]. Nevertheless, in the last years many attempts
have been made to identify molecular factors involved in
the development of a persister cell subpopulation. There is
increasing evidence that toxin-antitoxin modules, quorum-
sensing molecules, global transcriptional regulators, andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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Figure 1 Killing kinetics of S. suis exposed to different antibiotics.
Exponential (A) or stationary (B) grown S. suis strain 10 was treated
with 100-fold MIC of indicated antibiotics over time. The limit of
detection was defined as 100 CFU/ml throughout all killing experiments.
All lower bacterial numbers were considered as not detectable (n. d.).
The values are means of two biological replicates and error bars indicate
the standard deviation. An untreated culture without any antibiotic
challenge (w/o antibiotic) served as a control.
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volved in persister cell formation [4,9-13].
Since the first report by Bigger in 1944 [1], bacterial per-
sister cells have been described for a number of different
species, including Escherichia coli [14], Staphylococcus
aureus [14,15], Pseudomonas aeruginosa [16], and Myco-
bacterium tuberculosis [17,18]. For most of these bacterial
species persister cells have also been found in biofilms,
which contribute to recalcitrant and/or recurrent infec-
tions after antibiotic therapy [4,19-25].
Little is known about persister cell formation in strepto-
cocci [9,26]. Within pathogenic streptococci, the zoonosis
Streptococcus suis (S. suis) is of particular interest since it
can cause very severe diseases, such as sepsis, meningitis
and streptococcal toxic shock like syndrome in humans
who are in close contact to pigs or pig products [27-30].
Notably, S. suis has been shown to be one of the most fre-
quent causes of adult bacterial meningitis in Asian coun-
tries including Vietnam and Thailand [31,32]. S. suis
infections are widely distributed in pigs, but can also occur
in wildlife animals such as wild rabbits or wild boars
[33,34]. In pigs S. suis is a frequent early colonizer of the
upper respiratory tract. In young pigs S. suis is also a
major cause of meningitis, arthritis, and septicemia. Thus,
S. suis infections are a major concern in the swine produ-
cing industry as they lead to high financial losses [35].
Since antibiotics are widely used to control S. suis
infections (in humans and in animals), we examined the
ability of S. suis to produce antibiotic tolerant persister
cells. We analyzed the effects of the initial bacterial
growth phase on persister cell formation, the tolerance
of these cells to different types of antibiotics, as well as
persister cell levels of different S. suis strains and other
human pathogenic streptococci. Our results show for
the first time that S. suis forms high levels of persister
cells that confer tolerance to a variety of antimicrobial
compounds. We also present evidence that persister cell
formation is not only found in S. suis but also in other
streptococcal species.
Results
Identification of a multi-drug tolerant persister cell
subpopulation in S. suis
Since persister cell formation is important for antibiotic
tolerance and recurrent infections, we studied the occur-
rence of persister cells in the zoonotic pathogen S. suis
using a highly virulent serotype 2 strain, strain 10. First we
determined the minimal inhibitory concentration (MIC) of
six antibiotics with different modes of action for exponen-
tial grown S. suis strain 10 by the standard microdilution
assay (see Additional file 1: Table S1), because one main
characteristic of persister cells is the ability to tolerate con-
centrations of different antimicrobial compounds above
the MIC. Following, to test whether S. suis is capable ofproducing persister cells that tolerate antibiotic treatment,
we performed antibiotic killing experiments with a 100-
fold MIC of each antimicrobial compound. Antibiotic
challenge was performed with cultures grown either to ex-
ponential or stationary phase. Since a 100-fold MIC should
inactivate antibiotic-sensitive normal growing bacteria, we
assumed that this treatment would result in characteristic
biphasic-killing characterized by an initial rapid killing of
the bulk of the bacterial population followed by a distinct
plateau of surviving drug tolerant persister cells [6]. As
depicted in Figure 1A, gentamicin treatment of exponential
grown S. suis resulted in decrease of bacterial CFU by three
orders of magnitude within the first hour and a subsequent
plateau phase in the following hours. When we applied
β-lactam antibiotics and ciprofloxacin the killing was
not as pronounced as observed for gentamicin, neverthe-
less a slow decrease of life counts was seen over time.
Nearly no killing was observed after treatment with rifam-
picin. In contrast, daptomycin was able to completely kill
the bacterial population without detectable survival of per-
sister cells. These data indicate that within an exponential
grown S. suis culture a subpopulation of antibiotic tolerant
Figure 2 Test for the heritability of persistence and elimination
of persister cells. (A) Exponential grown S. suis strain 10 was treated
with 100-fold MIC of gentamicin for three hours, and at indicated time
points CFU were determined. Subsequently, surviving bacteria were
incubated in fresh THB media overnight, then grown to early logarithmic
phase and challenged with 100-fold MIC of gentamicin. This procedure
was repeated for four consecutive cycles. The values are means of three
biological replicates and error bars indicate the standard deviation.
(B) S. suis strain 10 was sequentially grown to early exponential growth
phase. At each cycle CFU of the initial inoculum and of surviving
bacteria after a one-hour 100-fold MIC gentamicin challenge were
determined. Data were expressed for each cycle as percentage of
surviving bacteria in relation to the initial inoculum before antibiotic
treatment. The dotted line represents the limit of detection. Standard
deviation is shown for three replicates.
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ance depending on the class of antibiotic.
Next we studied the persister cell levels of stationary
grown S. suis since for several other bacterial species a
drastic increase in persister levels has been reported at the
onset of stationary growth phase [4]. Antibiotic treatment
of stationary cultures of S. suis with 100-fold MIC resulted
in a substantial drug tolerance, i.e. a distinct biphasic kill-
ing pattern such as seen with exponential cultures was not
observed (Figure 1A vs. B). Only a slight decrease in num-
bers of CFU was detected over time after treatment with
β-lactams, ciprofloxacin and gentamicin. In the case of
gentamicin a relative difference of approximately three
logarithmic orders in CFU was recorded after the first
hour of antibiotic treatment, when comparing populations
of exponential and stationary grown S. suis. Notably,
growth to the stationary growth phase did not enhance
the tolerance of S. suis to the cyclic lipopeptide daptomy-
cin which completely killed the S. suis population after
only one hour of treatment. Taken together, the killing
kinetics revealed that under the conditions tested S. suis
develops a growth phase dependent subpopulation show-
ing antibiotic tolerance to a variety of antimicrobial com-
pounds except daptomycin.
The persister cell phenotype of S. suis is not inherited and
dominated by type I persisters
In contrast to genetically encoded antimicrobial resist-
ance, multidrug tolerance of persister cells is a transient
and non-heritable phenotype [10,26]. To test heritability
of antimicrobial tolerance, exponential grown S. suis was
treated with 100-fold MIC of gentamicin and the surviving
population was used to repeat a new cycle. Four consecu-
tive cycles were tested. Gentamicin was selected for these
experiments since this treatment resulted in pronounced
biphasic killing curves in the first hours after antibiotic
treatment. As depicted in Figure 2A, tolerance to gentami-
cin of the initial population was not transferred to follow-
ing S. suis generations. The characteristic biphasic killing
curve upon antibiotic treatment was observed irrespective
of the number of passages. These results suggest that the
formation of a S. suis persister cell subpopulation and
antimicrobial tolerance is not inherited and of transient
nature.
In order to dissect whether type I or type II persisters are
responsible for gentamicin tolerance, we performed a per-
sister cell elimination assay. In this assay the formation of
type I persisters is suppressed by sequential re-inoculation
of an early exponential culture. This procedure leads to di-
lution of type I persisters whilst stochastically build type II
persister cell levels should remain constant. As depicted in
Figure 2B the percentage of antibiotic tolerant persisters
decreased sequentially after 100-fold MIC gentamicin chal-
lenge when the bacterial culture was kept in the earlygrowth phase for three cycles. This data indicate that gen-
tamicin tolerant persisters are not or only rarely produced
in the early exponential growth phase and that most of the
tolerant bacteria represented type I persisters. These were
probably ‘left overs’ from the overnight culture and became
diluted within repeated cycles of exponential growth.
S. suis persister cells also tolerate combinations of
different antibiotics
Antibiotics like penicillin are frequently used to treat S.
suis infections, sometimes in combination with other an-
tibiotics like aminoglycosides. However, relapses of S.
suis infections in pigs and humans have been reported
[36]. Furthermore, penicillin and gentamicin are widely
used in standard antibiotic protection assays to quantify
intracellular bacteria in in vitro cell culture experiments.
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bination of penicillin (200-fold MIC) and gentamicin (4-
fold MIC) that correspond to the concentrations applied
in these antibiotic protection experiments. After simultan-
eous treatment of exponential grown S. suis with penicillin
and gentamicin we observed a biphasic killing curve char-
acterized by a rapid decrease of CFU numbers within the
first hour and a subsequent plateau of surviving bacteria
persisting for more than 8 hours (Figure 3A). The killing
kinetics of stationary grown bacteria treated similarly re-
sembled treatment with gentamicin alone, as depicted in
Figure 1B. Similar to what we observed after treatment
with a single antibiotic, the tolerance to a combination of
penicillin and gentamicin was not inherited, as revealed
from heritability tests (Figure 3B). These data suggest that
S. suis persister cells are capable of tolerating not only sin-
gle antibiotics, but also a combination of penicillin and
aminoglycosides.Figure 3 Time-dependent killing after combined antibiotic
treatment. (A) Exponential (solid line) and stationary (dotted line)
grown S. suis strain 10 was exposed to a combined antibiotic
treatment of 200-fold MIC of penicillin and 4-fold MIC of gentamicin
over time. (B) This penicillin/gentamicin combination was also used
in a heritability test with exponential (solid line) and stationary
(dotted line) grown S. suis in three consecutive cycles. The values
are means of two biological replicates plated in triplicate. Error bars
indicate the standard deviation.Persister cell formation in S. suis is affected by the global
transcriptional regulator CcpA and the catabolic arginine
deiminase system
Several genes and gene products have been implicated in
antibiotic tolerance, like toxin-antitoxin (TA) modules,
quorum-sensing molecules and global transcriptional reg-
ulators [4,9]. In previous studies we have shown that CcpA
is a pleiotropic regulator of S. suis carbon metabolism,
virulence gene expression and the expression of the argin-
ine deiminase (AD) system [37-39]. The latter is crucial
for bacterial survival in acidic environments and is most
likely required for alternative ATP generation. Hence, we
tested respective S. suis mutant strains 10ΔccpA and
10ΔAD for gentamicin tolerant persister cells. CFU of
bacterial strains grown to the exponential growth phase
were determined over time after treatment with 100-
fold MIC gentamicin. The gentamicin MIC values of
the mutant strains did not differ from those of the wild
type strain. No change in persister levels was observed
for exponential grown strain 10ΔccpA, whereas the AD
mutant strain 10ΔAD showed an approximately two
log-fold higher persister cell level over time compared
to the wild type (Figure 4A). This difference was abro-
gated when stationary growth phase cultures were chal-
lenged by gentamicin (Figure 4B). Interestingly, during
the later growth phase the persister level of strain
10ΔccpA decreased as compared to the wild type and
strain 10ΔAD.
Persister cell formation occurs in different S. suis strains
and streptococcal species
Next, we tested antibiotic tolerance and persister cell for-
mation in other S. suis strains and streptococcal species.
For this, we analyzed a human serotype 2 isolate (strain
05ZYH33) originating from a S. suis outbreak in China
and a serotype 9 strain (strain A3286/94) isolated from a
pig with meningitis [40,41]. The MIC values of gentamicin
for strain 05ZYH33 and strain A3286/94 are given in
Additional file 1: Table S1. In all strains, treatment with
100-fold MIC of gentamicin induced the characteristic
biphasic killing curve and resulted in a complete killing of
bacteria after 24 hours. No substantial differences could
be observed between strains in the exponential growth
phase (Figure 5). On the other hand, using stationary
cultures strain 10 showed the highest degree of drug toler-
ance. Strains A3286/94 and 05ZYH33 were killed more
efficiently, especially during the first hour of antibiotic
treatment, with persister cell differences of up to two log-
fold CFU. After 24 hours of gentamicin treatment viable
bacteria could only be recovered in strain 10, but not in
strains A3286/94 and 05ZYH33, respectively (data not
shown). These data indicate that various S. suis strains
and serotypes form persisters with different frequencies
and antibiotic tolerance characteristics.
Figure 4 Effect of specific gene inactivation on S. suis persister
formation. Exponential (A) or stationary (B) grown S. suis strains
were treated with 100-fold MIC of gentamicin over time. Persister
cell levels were determined for the wild type strain 10, and its
knock-out mutant strains 10ΔccpA and 10ΔAD, which lack the genes
coding for the global transcriptional regulator CcpA and the catabolic
arginine deiminase system, respectively. The values are means of three
biological replicates and error bars indicate the standard deviation.
Significant differences to wildtype persister levels were calculated by a
one-tailed t-test (*, P < 0.05; **, P < 0.01).
Figure 5 Persister cell levels of different S. suis strains.
Exponential (A) or stationary (B) grown S. suis strains were treated
with 100-fold MIC of gentamicin over time. Persister cell levels were
determined for the porcine serotype 2 isolate strain 10, a porcine
serotype 9 isolate strain A3286/94, and a human serotype 2 isolate
strain 05ZYH33. The values are means of two biological replicates
and error bars indicate the standard deviation.
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streptococcal species [42-44] we studied persister cell for-
mation in selected strains of other streptococci, including
S. pyogenes, S. agalactiae, and S. gordonii after treatment
with 100-fold MIC gentamicin. The determined MIC
values for each strain are listed in Additional file 1: Table
S1. Interestingly, in contrast to S. suis neither exponential
nor stationary grown streptococci of the tested strains
displayed a gentamicin tolerant subpopulation (data not
shown). Notably, we could not detect any gentamicin
tolerant subpopulation for S. pyogenes, S. gordonii, and
S. agalactiae overnight cultures as shown in Figure 6A.
On the other hand, treatment with 100-fold MIC of
ciprofloxacin resulted in a drug-specific tolerance for at
least 8 hours (Figure 6B). The proportion of ciprofloxacin
tolerant bacteria was higher for S. suis strain 10 and S.
pyogenes strain A40 as compared to the other streptococ-
cal species. These data indicate that drug tolerant subpop-
ulations might also occur in other streptococcal species,
but the extent of tolerance seems to vary between differ-
ent antibiotics.Discussion
Generation of bacterial persister cells is important not only
with respect to the understanding of population dynamics
but also concerning antibiotic tolerance in respective
therapy of infections [45]. Accordingly, there is growing
evidence that bacterial persisters are involved in relapses of
refractory bacterial infections and in the establishment of
resistance mechanisms in bacteria [21]. Owing to this it
seems not surprising that persister cells have been de-
scribed for numerous pathogenic bacteria. In this study we
have shown for the first time that S. suis forms multi-drug
tolerant persister cells. Even though 100-fold MIC is
unlikely to be achieved in therapy of natural infections, we
assumed that this treatment would be a method of choice
to identify highly drug-tolerant persister cells of S. suis in
accordance to results reported for S. aureus [15]. By this
we identified persister cell formation in three different S.
suis strains, suggesting that this phenomenon may be a
general trait among this species. Though this has to be
further confirmed by testing more S. suis strains and
antibiotics that are of higher clinical relevance to treat
S. suis infections in pigs and humans, persister cells
should be considered in the future in cases of
Figure 6 Persister cell levels of selected human pathogenic
streptococci. Overnight cultures of indicated streptococcal strains
were treated with 100-fold MIC of gentamicin (A) or 100-fold MIC of
ciprofloxacin (B) over time. The values are means of two biological
replicates and error bars indicate the standard deviation.
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biotic tolerance of S. suis.
In line with several previous studies [3,14,22,46] the
number of persisters observed was higher during stationary
growth of S. suis when compared to exponential grown
bacteria. Type I persisters were found to be the main
source of antibiotic tolerance in our experiments. Among
other stress signals, nutrient limitation in stationary growth
is thought to be a trigger inducing down-regulation of the
metabolic activity and bacterial dormancy in energy-
deprived cells which can protect the bacteria from anti-
biotic killing. We found some hints for involvement of the
catabolic enzyme system ADS, since approximately two
log-fold higher levels of persister cells were found in the
exponential growth phase of an arginine deiminase knock-
out strain (10ΔAD) as compared to its wild type strain. In
S. suis the arginine deiminase system metabolizes arginine
as a substrate to produce energy in form of ATP [38]. The
diminished ATP levels may lead to reduced general meta-
bolic activity of strain 10ΔAD that might explain the
slower growth rate (see Additional file 2: Figure S1) and
enhanced number of antibiotic tolerant persister cells.
Furthermore, the ccpA deficient strain exhibited lower
numbers of persister cells in the stationary growth phase
when compared to the wild type. This is in agreement with
studies in S. gordonii showing that a ccpA knock-out re-
sulted in an increased sensitivity of the bacteria to penicil-
lin treatment [47]. Since CcpA is a pleiotropic regulatorthat is important for a balanced metabolic flux in the cen-
tral carbon metabolism, the alteration of central metabolic
processes may influence persister cell formation of S. suis.
Accordingly, an interplay between carbohydrate consump-
tion and formation of persisters has recently been demon-
strated for E. coli [12]. Further studies are needed to clarify
the mechanisms involved in CcpA and/or arginine deimi-
nase dependent changes in antibiotic tolerance of S. suis.
When using antibiotics with varying modes of action,
resulting killing profiles were quite different, ranging from
pronounced biphasic killing patterns to nearly plane
curves, at least for exponential grown S. suis. These find-
ings seem to be highly dependent on the type of antibiotic
used, which is also emphasized by the fact that treatment
with the β-lactam antibiotics amoxicillin and penicillin
resulted in similar killing curves. Thus we speculated a
common mechanism of tolerance for certain antibiotics
and tested the gentamicin tolerance in other streptococcal
species. S. suis strain 10 highly tolerated 100-fold MIC of
gentamicin, whereas the other streptococcal strains were
completely killed after one hour. These data suggest that a
specific mechanism for gentamicin tolerance of S. suis
persisters may have evolved and that this is, most likely,
not due to a shared genetic background within the genus
Streptococcus. Interestingly, after gentamicin treatment of
S. suis we also observed a small-colony-variant (SCV) like
phenotype (data not shown) that has also been reported
for S. aureus upon aminoglycoside treatment [15,48]. Al-
though it reverted to the typical large-colony phenotype
after subcultivation, it remains to be elucidated if this
phenotype will change to a stable phenotype after longer
exposure times and altered antibiotic tolerance to amino-
glycosides. However, at the stationary growth phase the
investigated S. suis strain 10 highly tolerated several anti-
microbials targeting different bacterial components over
time. Given the high rate of multi-drug tolerant cells pro-
duced by S. suis strain 10 during stationary growth, it was
remarkable that the cyclic lipopeptide daptomycin effi-
ciently eradicated this subpopulation. This is in contrast
to observations that in S. aureus 100-fold MIC of dapto-
mycin failed to eradicate stationary phase cultures [15].
Even though the MIC for daptomycin is rather high when
compared to that of other streptococcal species [49] this
treatment eradicated S. suis persister cells in vitro.
In the last years bacterial persistence and enhanced anti-
biotic tolerance was intensively discussed in the context of
recurrent infections caused by bacterial pathogens. Inter-
estingly, a human case of recurrent septic shock due to a
S. suis serotype 2 infection has previously been reported
[50]. Together with our present study this suggests a clin-
ical relevance of S. suis persisters. Although experimental
evidence for S. suis persister cell and biofilm formation
in vivo is yet missing, S. suis is able to produce biofilms
in vitro that tolerate antibiotic challenge [51,52]. Given
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100% [35,53,54] and that antibiotic treatment with penicil-
lin, ampicillin, or ceftiofur failed to eliminate the tonsillar
carrier state of S. suis in swine [55], it is plausible to
speculate that persister cells, possibly also as part of bio-
film structures, may contribute to the observed problems
in antibiotic treatments. Indeed, P. aeruginosa persister
cells have been described as the dominant population
responsible for drug tolerance in biofilms [22].
Conclusions
Our study showed that the zoonotic pathogen S. suis is
able to form a multi-drug tolerant persister cell subpop-
ulation. S. suis persister cells tolerated a variety of anti-
microbial compounds that were applied at 100-fold of
MIC and could be detected in different S. suis strains.
Thus, our study provides a basis for future studies on
the role of S. suis persister cells in bacterial colonization
of host tissues, general antibiotic tolerance, and recur-
rent infections.
Methods
Bacterial strains, media, and growth conditions
All bacterial strains investigated in this study (listed in
Table 1) were grown in complex Todd Hewitt Broth
(THB, Becton Dickinson Diagnostics) medium at 37°C.
If not stated otherwise cryo-conserved bacterial stocks
were used in the experiments. Preliminary experiments
with cryo-conserved and freshly prepared bacterial cul-
tures had revealed no significant differences in persister
cell formation assays (data not shown), similar to what
has been reported for E. coli [6]. For the preparation of
bacterial stocks, overnight cultures were diluted to an
optical density at 600 nm (OD600) of 0.02 in fresh THB
medium and further incubated until bacteria reachedTable 1 Bacterial strains used in this study
Strain Description Reference
S. suis
10 Virulent serotype 2 strain, porcine isolate [56]
10ΔccpA Strain 10 ccpA mutant; ccpA::EmR [39]
10ΔAD Strain 10 arginine deiminase operon
mutant; arcA::SpcR
[38]
05ZYH33 Virulent serotype 2 strain, isolate from
human outbreak in China
[40]
A3286/94 Virulent serotype 9 strain, porcine isolate [41]
S. agalactiae




A40 A clinical isolate belonging to M type 12 [59]either the early exponential (exp) or stationary (stat)
growth phase as depicted in Additional file 2: Figure S1.
Then 19 ml of exponential grown or 4 ml of stationary
grown bacterial cultures were collected and centrifuged
at 4000 × g for 10 min at 4°C. Bacterial pellets were
washed once in phosphate-buffered saline, resuspended
in THB medium containing 15% glycerol (v/v), and ali-
quots were immediately shock frozen in liquid nitrogen.
Frozen cultures were kept at −80°C until use and num-
bers of viable cells were determined by serial plating on
sheep blood Columbia agar plates. All antibiotic treat-
ments were performed in chemically defined medium,
RPMI 1640 (Life Technologies), which is routinely used
in cell culture.
Antibiotics and determination of minimal inhibitory
concentration (MIC)
Daptomycin (commercial Cubicin®) analytic grade powder
was purchased from Novartis Pharma. Penicillin G, cipro-
floxacin, amoxicillin, and rifampicin were purchased from
Sigma, and gentamicin from Roth. The antimicrobial solu-
tions were prepared freshly prior to each application ac-
cording to the manufacturers’ recommendations.
The MIC of each antibiotic was determined in duplicate
by the microdilution technique in 96-well plates. Serial
two-fold dilutions of different antibiotics prepared in
RPMI 1640 medium were inoculated each with 5 × 105
colony forming units (CFU) of exponential grown cryo-
conserved bacteria per well. MICs were also determined
for freshly prepared bacterial cultures and did not signifi-
cantly differ from MICs of cryo-conserved bacteria (data
not shown). Plates were covered with a Breathe-Easy®
sealing membrane to avoid evaporation and incubated for
24 hours at 37°C. The lowest antibiotic concentration that
inhibited visible bacterial growth was defined the MIC.
The determined MIC values are listed in Additional file 1:
Table S1.
Test for persister cell formation
Chemically defined RPMI 1640 medium was inoculated
with 1 × 107 CFU of either exponential or stationary
grown cryo-conserved bacteria. Freshly prepared anti-
microbial substances were added at a final concentration
of 100-fold MIC, if not stated otherwise. Suspensions were
incubated with end-over-end rotation at 37°C. Samples
were taken after 1, 2, 4, 6, and 8 hours for determination
of CFU by serial dilution and plating. For this 100 μl of
bacterial suspensions were immediately harvested by cen-
trifugation, once washed in sterile 0.85% NaCl solution
and spotted as 10 μl aliquots on sheep blood Columbia
agar plates in serial dilutions. Plating of the aliquots was
performed in triplicates and all antibiotic killing experi-
ments were performed at least with two biological repli-
cates. Bacterial colonies were counted 24 and 48 hours
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ing bacteria. The results were analyzed with the GraphPad
Prism 5 software and expressed in CFU/ml on a logarith-
mic scale. The limit of detection was defined as 100 CFU/
ml and lower bacterial numbers were considered not
detectable (n. d.). If indicated statistical significance was
determined by one-sided Student t test.
Heritability of persistence
An overnight culture was diluted to an OD600 of 0.02 in
fresh THB medium and further incubated until the early
exponential growth phase was reached. Then bacteria
were harvested by centrifugation, once washed with PBS,
and inoculated in fresh RPMI medium containing 100-
fold MIC of the respective antibiotic to a final bacterial
concentration of 1 × 107 CFU/ml. The suspensions were
incubated at 37°C with moderate end-over-end rotation.
Samples were taken hourly as indicated and the CFUs
were determined after removal of remaining antibiotics by
washings as described above. After 3 hours of antibiotic
treatment (surviving) bacteria were collected by centrifu-
gation, once washed in PBS, inoculated in fresh THB
medium and grown overnight. This culture was then used
to start a new cycle of antibiotic treatment with exponen-
tial grown bacteria. This procedure was repeated with
three consecutive cycles and the experiment performed at
least with two biological replicates. Colonies were counted
and CFUs calculated as described above.
Test for persister cell elimination
To dissect whether the antibiotic tolerant persister popu-
lation of S. suis strain 10 comprises type I or type II per-
sister cells, we performed a persister cell elimination test
as described by Keren et al. [14], with some modifications.
Briefly, an overnight culture of S. suis strain 10 was ad-
justed to OD600 = 0.02 in fresh THB medium and further
incubated until bacteria reached OD600 = 0.2. Then, ali-
quots of this culture were used to inoculate fresh THB
medium to OD600 = 0.02 for a further cycle and to deter-
mine persister cell levels after a 100-fold MIC gentamicin
challenge. A gentamicin challenge was done as described
for the test of heritability of persistence with the exception
that the antibiotic treatment lasted one hour. Dilution-
growth cycles with subsequent antibiotic challenge were
repeated thrice. For each cycle the initial inoculum before
and the surviving bacteria after antibiotic challenge were
determined by CFU counting. Data were expressed as per-
centage of surviving bacteria in relation to the initial in-
oculum before antibiotic treatment.
Additional files
Additional file 1: Table S1. MIC values of antimicrobial compounds
(μg/ml) for different streptococcal strains. ND stands for ‘not determined’.Additional file 2: Figure S1. Growth kinetics of selected S. suis strains,
isogenic mutants of S. suis strain 10, and strains of other streptococcal
species in THB medium. For antibiotic tolerance assays bacteria were
grown in complex THB medium and harvested at an OD600nm of 0.2,
reflecting the early exponential growth phase, or at the stationary growth
phase of each strain that is indicated by a red coloured symbol in the
graph. (A) Growth curves of selected S. suis strains and isogenic mutants
of S. suis strain 10. (B) Growth curves of selected strains of other
streptococcal species.
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